Pricing strategy for the UAE pharmaceutical market

Getting a medicine registered in the United Arab Emirates is only half the market access story. The price the authority approves shapes the commercial case for launch, and because the UAE benchmarks against other markets, the decisions you make abroad can move your UAE price. This guide explains how pharmaceutical pricing works in the UAE and how foreign manufacturers can approach it strategically.

Who sets medicine prices in the UAE

Medicine prices in the UAE are regulated centrally. A federal pricing committee reviews and approves the price of each registered product rather than leaving it to the open market. Historically this function sat with the Ministry of Health and Prevention (MOHAP). As part of a wider regulatory consolidation, pricing responsibility is moving under the Emirates Drug Establishment (EDE), the federal authority now taking over the registration and pricing services previously run by MOHAP.

Because this transition is ongoing, the precise route, the documents requested, and the methodology applied can shift. Treat the official pricing rules as a moving target and confirm the live requirements with the authority before you build a submission around them.

How external reference pricing works

The UAE relies heavily on external reference pricing. In simple terms, the proposed price for a product is not assessed in isolation. It is benchmarked against the prices of the same product in a defined basket of comparator countries together with the product's country of origin. The committee then uses those references to anchor what it is prepared to approve.

The practical effect is that the approved UAE price tends to settle towards the lower end of the available references rather than the highest. If your product is cheaper in one of the reference markets, that lower figure can act as a pull on the UAE price. For a manufacturer, this means your UAE outcome is partly determined by pricing decisions taken in other countries, sometimes long before the UAE submission is even prepared.

We are deliberately not listing the specific comparator countries or quoting formulas or percentages here, because the reference basket and the exact calculation method can change. The current methodology should always be confirmed with the authority or your regulatory partner at the time of submission.

Building a pricing strategy that anticipates the reference

Once you understand that the UAE price is benchmarked, the strategy follows. The goal is to reach the UAE pricing committee with a defensible, well-positioned reference picture rather than a set of inconsistent international prices that drag your outcome down.

Launch price positioning

The price you launch at internationally is not just a local decision. Because it can become a reference point for the UAE, the launch price needs to be set with the downstream benchmarking in mind. A price that looks attractive for a single early market may quietly undercut your position in every market that later references it, the UAE included.

Sequence and timing of launches

The order in which you enter markets matters. If you launch first in a country that sits in the UAE reference basket at a low price, that figure can be visible to the UAE committee and pull the UAE approval downward. Planning the sequence of launches, and the timing of each one relative to the UAE submission, is one of the most powerful levers in a global pricing plan.

Currency considerations

External reference pricing involves comparing prices across currencies, so exchange rate movements can change how a foreign price translates into the UAE benchmark. A reference that looked acceptable when set can drift as currencies move, which is worth modelling rather than assuming a static picture.

Lifecycle repricing

A UAE price is not necessarily fixed for the life of the product. Prices can be reviewed and re-evaluated over time, so a sound strategy plans for re-evaluation from the outset. Mapping how the reference markets are likely to move, and where future re-evaluations could land, helps you avoid an erosion that takes the commercial case by surprise.

Why this is hard to manage in isolation

Pricing in the UAE sits at the intersection of global commercial strategy and local regulatory procedure. The figures that drive your approval are partly set in markets your UAE team may not control, and the methodology itself can change during the current transition. That is why most foreign manufacturers coordinate their UAE pricing submission with a local regulatory partner who tracks the live committee requirements and can position the reference picture correctly. You can read more about our pharmaceutical registration services to see how pricing fits into the wider market access workflow.

This guide is general information, not regulatory or legal advice. UAE pricing requirements are actively changing during the MOHAP to EDE transition; the reference basket and methodology can change, so confirm the current pricing methodology with the relevant authority or your regulatory partner before acting. Related: pharmaceutical registration services.